Gabapentin
Treatment for Menopause
Typical Dosage: 300-900mg orally daily, often dosed at bedtime
Effectiveness
65%
Safety Score
65%
Clinical Trials
6
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
65
DangerousModerateSafe
Treatment Details
Dosage Range
300-900mg orally daily, often dosed at bedtime
Time to Effect
1-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2000(Treat 2000 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$270
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$469.57
Cost per Remission
$1,080
Gabapentin Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+57.5%
Remission Rate
+25%
Common Side Effects
Dizziness
+20%
Somnolence/Sedation
+15%
Headache
+7%
Peripheral edema
+7%
Weight gain
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Gabapentin in Menopause
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
NCT06049797ACTIVE NOT RECRUITING
999 participants
OBSERVATIONAL
Birmingham, United States +47 more
Started: Nov 15, 2023
Completed Clinical Trials
5 completed trials for Gabapentin in Menopause
Gabapentin for the Treatment of Hot Flashes in Menopausal Women
NCT00112138COMPLETEDPHASE3
200 participants
INTERVENTIONAL
Scarborough Village, Canada
Started: Mar 1, 2004
Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
NCT02040532COMPLETEDNA
32 participants
INTERVENTIONAL
Boston, United States +1 more
Started: Jan 1, 2014
The Menopause After Cancer Study
NCT04766229COMPLETEDPHASE2
205 participants
INTERVENTIONAL
Dublin, Ireland +1 more
Started: Jun 21, 2021
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
NCT01080300COMPLETEDPHASE3
600 participants
INTERVENTIONAL
Birmingham, United States +65 more
Started: Aug 1, 2010
Gabapentin Versus Estrogen for the Treatment of Hot Flashes
NCT00276081COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Rochester, United States
Started: May 1, 2002